HUE028589T2 - Gyógyászati készítmény rák kezelésére és megelõzésére - Google Patents

Gyógyászati készítmény rák kezelésére és megelõzésére Download PDF

Info

Publication number
HUE028589T2
HUE028589T2 HUE09794512A HUE09794512A HUE028589T2 HU E028589 T2 HUE028589 T2 HU E028589T2 HU E09794512 A HUE09794512 A HU E09794512A HU E09794512 A HUE09794512 A HU E09794512A HU E028589 T2 HUE028589 T2 HU E028589T2
Authority
HU
Hungary
Prior art keywords
ser
thr
gly
leu
val
Prior art date
Application number
HUE09794512A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Takayoshi Ido
Masaki Shimizu
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of HUE028589T2 publication Critical patent/HUE028589T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Claims (5)

  1. GYÓGYÁSZATI KÉSZÍTMÉNY RÁK KEZELÉSÉRE ÉS MEGELŐZÉSÉRE Szabadalmi Igénypontok
    1, Antitest rákterápiás és/vagy rákmegelőzési eljárásban történő alkalmazásra, amely antitest immunreaktivitást mutat egy CD179b fehérjével szemlsen, amely rendelkezik a EEG ID NO:3-ban (azaz 3~as azonosítási számö szekvenciában! bemutatót aminosav-szekvenciával, ahol az antitest képes effektöísejíek által antiiest-dependens sejt-mediáit cítotoxicltás (ADCC) és €D17§~expresszáló sejtekkel szembeni kompfementfüggö cítotoxicltás (CDC) mediálására,
  2. 2, .Az antitest alkalmazásra az 1. igénypont szerint, ahol a rák leukémia vagy límfóma. 3> Az antitest alkalmazásra az 1. vagy 2. Igénypont szerint, ahol az antitest monoklonáüs antitest vagy poliklonális antitest.
  3. 4, Az antitest alkalmazásra az 1-3. Igénypontok bármelyike szerint, ahol az antitest humán antitest, humanizált antitest, klméra antitest, egylánoú antitest vagy bispecifikus antitest. δ. Antitest, amely tartalmaz olyan nehézláno variábilis régiót, amely rendelkezik a EEG ID ND: 103-ban bemutatott CDR1 aminosav-szekvenciával, a SEQ ID Nö: 104-ben bemutatott CDR2 aminosav-szekvenciával, és a EEG ID NO :102-ben bemutatott ODR3 aminosav-szekvenciával, és tartalmaz olyan könnyülánc variábilis régiót, amely rendelkezik a SEQ 10 NO: 108-ban bemutatott CDR1 aminosav-szekvenciával, a SEQ ID NO: 107-ben bemutatott CDR2 aminosav-szekvenciával, és a SEQ ID NO: 108-ban bemutatott CD.R3 aminosav-szekvenciával, az antitest immunreaktivitást mutat egy CDI 79b fehérjével szemben, ahol az antitest képes effektorseftek általi antítesí-dependens sejt médiáit citotoxicitás (ADCC) ès €D179-expresszálő sejtekkel szembeni komplementfüggö citotoxicitás {CDC} medlálására.
  4. 8, Az 5. igénypont szedeti antitest:, amely tartalmaz olyan nehézlánc variábilis régiót, amely rendelkezik a 8EG ID Hö: 105-ben bemutatott sminosav-szekvenciával, és olyan könnyöláne variábilis régiót, amely rendelkezik a 8EQ ID NO: 109-ben bemutatott aminosav-szekvenciával. ?, Az 5, vagy 8. igénypont szerinti antitest, amely humanizált antitest, kimére antitest, egyfáncú antitest vagy bispeciflkus antitest, S. Az 5-7. Igénypontok bármelyike szerinti antitest gyógyászati kezelési eljárásban történő alkalmazásra. i> Az antitest alkalmazásra az 1-4. Igénypontok bármelyike szerint, ahol: az antitest az 5-7. igénypontok bármelyike szerinti antitest.
  5. 10. Gyógyászai készítmény, amely hatásos összetevőként tartalmaz az 5-7. igénypontok bármelyike szerinti: antitestet. 11 DNS, amely kódolja az 5-7. igénypontok bármelyike szerinti antitestet.
HUE09794512A 2008-07-10 2009-07-10 Gyógyászati készítmény rák kezelésére és megelõzésére HUE028589T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008180057 2008-07-10
JP2009087379 2009-03-31

Publications (1)

Publication Number Publication Date
HUE028589T2 true HUE028589T2 (hu) 2016-12-28

Family

ID=41507178

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09794512A HUE028589T2 (hu) 2008-07-10 2009-07-10 Gyógyászati készítmény rák kezelésére és megelõzésére

Country Status (16)

Country Link
US (2) US10611835B2 (hu)
EP (1) EP2305300B1 (hu)
JP (1) JP5573156B2 (hu)
KR (1) KR101669834B1 (hu)
CN (1) CN102089004B (hu)
AU (1) AU2009270181B2 (hu)
BR (1) BRPI0910509B8 (hu)
CA (1) CA2730201C (hu)
DK (1) DK2305300T3 (hu)
ES (1) ES2575430T3 (hu)
HU (1) HUE028589T2 (hu)
MX (1) MX2011000117A (hu)
PL (1) PL2305300T3 (hu)
PT (1) PT2305300E (hu)
RU (1) RU2533460C2 (hu)
WO (1) WO2010005068A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
WO2016168760A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
KR20170141660A (ko) 2015-04-30 2017-12-26 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US10968275B2 (en) 2016-02-02 2021-04-06 Fred Hutchinson Cancer Research Center Anti-ROR1 antibodies and uses thereof
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2014073A (en) * 1935-09-10 Stovepipe
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP1001020A4 (en) 1997-07-29 2005-03-02 Sumitomo Electric Industries NON-HUMAN PRE-B CELL RECEPTOR ANTIBODIES
ES2364266T3 (es) 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
WO2001077332A2 (en) 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
KR101412271B1 (ko) * 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
JPWO2005083074A1 (ja) 2004-03-01 2007-11-22 有限会社金沢大学ティ・エル・オー 腫瘍抗原ペプチド
RU2429245C2 (ru) 2004-03-30 2011-09-20 Глаксо Груп Лимитед Иммуноглобулины
EP1774043A4 (en) 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
EP2380908A1 (en) * 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008141197A1 (en) 2007-05-10 2008-11-20 Sea Lane Biotechnologies, Llc Chain reaction creating oligomers from repeat units of binding molecules
KR101323192B1 (ko) 2008-07-10 2013-10-30 도레이 카부시키가이샤 면역 유도제 및 암의 검출 방법
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
RS62387B1 (sr) * 2010-01-29 2021-10-29 Chugai Pharmaceutical Co Ltd Anti-dll3 antitelo
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Also Published As

Publication number Publication date
RU2011104709A (ru) 2012-08-20
MX2011000117A (es) 2011-02-25
JP5573156B2 (ja) 2014-08-20
BRPI0910509B8 (pt) 2021-05-25
EP2305300A1 (en) 2011-04-06
RU2533460C2 (ru) 2014-11-20
DK2305300T3 (en) 2016-06-06
CA2730201A1 (en) 2010-01-14
ES2575430T3 (es) 2016-06-28
CN102089004A (zh) 2011-06-08
US20200247888A1 (en) 2020-08-06
US20110129478A1 (en) 2011-06-02
BRPI0910509B1 (pt) 2021-05-04
EP2305300A4 (en) 2011-11-02
AU2009270181B2 (en) 2014-05-29
BRPI0910509A2 (pt) 2015-09-29
US10611835B2 (en) 2020-04-07
JPWO2010005068A1 (ja) 2012-01-05
KR20110039423A (ko) 2011-04-18
CN102089004B (zh) 2018-06-01
AU2009270181A1 (en) 2010-01-14
CA2730201C (en) 2019-02-05
KR101669834B1 (ko) 2016-10-27
PL2305300T3 (pl) 2016-09-30
EP2305300B1 (en) 2016-04-06
WO2010005068A1 (ja) 2010-01-14
PT2305300E (pt) 2016-06-16

Similar Documents

Publication Publication Date Title
EP2740489B1 (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
DK2740796T3 (en) Pharmaceutical composition for the treatment and / or prevention of cancer
US9428581B2 (en) Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
AU2013223143B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CA2864999C (en) Pharmaceutical composition for treatment and/or prevention of cancer
EP2322221B1 (en) Pharmaceutical composition for treatment and prevention of cancer
EP2532743B1 (en) Pharmaceutical composition for treatment and/or prevention of cancer
DK2740793T3 (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
EP2532366B1 (en) Pharmaceutical composition for treating and/or preventing cancer
HUE033183T2 (hu) Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény
HUE034736T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
HUE030137T2 (hu) Rák kezelésére és/vagy megelõzésére szolgáló gyógyszerkészítmény
WO2013147169A1 (ja) 肝臓癌の治療及び／又は予防用医薬組成物
US20200247888A1 (en) Pharmaceutical composition for treatment and prevention of cancer
EP3290051B1 (en) Pharmaceutical composition for treating and/or preventing cancer